Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ricolinostat Liquid Formulation + Pom/Dex in RRMM
NCT02189343Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2014
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ricolinostat in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Maximum Tolerated Dose at 4 months. Started Sep 2014; status: completed.
02
Drugs
ricolinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02189343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02189343.